Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment.
about
Yoga for asthmaYoga for asthmaPreclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthmaA Systematic and Narrative Review of Acupuncture Point Application Therapies in the Treatment of Allergic Rhinitis and Asthma during Dog DaysA novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthmaMepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potentialEffect of switching to a high-deductible health plan on use of chronic medicationsThe impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysisStructuring and validating a cost-effectiveness model of primary asthma prevention amongst children.Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting.Frequent cough in unsatisfactory controlled asthma--results from the population-based West Sweden Asthma study.The active patient role and asthma outcomes in an underserved rural communityMedication prescribing for asthma and COPD: a register-based cross-sectional study in Swedish primary care.Opposing effects of low molecular weight heparins on the release of inflammatory cytokines from peripheral blood mononuclear cells of asthmatics.In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparinNon-Anticoagulant Fractions of Enoxaparin Suppress Inflammatory Cytokine Release from Peripheral Blood Mononuclear Cells of Allergic Asthmatic Individuals.Adopting Clean Fuels and Technologies on School Buses. Pollution and Health Impacts in Children.Prevention of Influenza Virus-Induced Immunopathology by TGF-β Produced during Allergic Asthma.Improved asthma control in patients with severe, persistent allergic asthma after 12 months of nightly temperature-controlled laminar airflow: an observational study with retrospective comparisons.National asthma observational survey of severe asthmatics in Israel: the no-air studyAsthma Economic Costs in Adult Asthmatic Patients in Tehran, Iran.A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaEconomic analysis of temperature-controlled laminar airflow (TLA) for the treatment of patients with severe persistent allergic asthma.Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells.Asthma genetics: personalizing medicine.The Clinical and Health Economic Value of Clinical Laboratory DiagnosticsImpact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).Asthma 2008: targeting immunoglobulin E to achieve disease control.Factors Affecting Recovery Time of Pulmonary Function in Hospitalized Patients With Acute Asthma Exacerbations.The validity of induced sputum and bronchoalveolar lavage in childhood asthma.Exploration of the Sphingolipid Metabolite, Sphingosine-1-phosphate and Sphingosine, as Novel Biomarkers for Aspirin-exacerbated Respiratory Disease.Activity of the cyclooxygenase 2-prostaglandin-E prostanoid receptor pathway in mice exposed to house dust mite aeroallergens, and impact of exogenous prostaglandin E2.Subtypes of asthma based on asthma control and severity: a latent class analysisMyAirCoach: the use of home-monitoring and mHealth systems to predict deterioration in asthma control and the occurrence of asthma exacerbations; study protocol of an observational study.Feasibility of Deploying Inhaler Sensors to Identify the Impacts of Environmental Triggers and Built Environment Factors on Asthma Short-Acting Bronchodilator Use.The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma.Asthma/COPD drugs reflecting disease prevalence, patient adherence and persistence.Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs.Evidence-based risk assessment and recommendations for physical activity clearance: respiratory disease.The relationship between allergen immunotherapy and omalizumab for treating asthma.
P2860
Q24185858-84472427-1A72-4FC6-8294-1FE9AFEBB704Q24201212-BE99AB6D-4C52-4694-BA8C-3497C8D611E2Q24620510-902E7D6D-1903-4ED5-9EB9-32E402D71959Q26778799-7A35F287-FB35-48A0-B457-6559EE33FCACQ27689386-61DA1147-54BB-4534-9666-7C96424066EDQ28080207-867B01D8-31E6-4240-B9B9-9A68E055AF34Q28743191-92DBBE3F-5B09-46FA-81FA-D60873252628Q33697776-D3D88991-4D7F-4C68-BAB2-F3F8A84EB12EQ34070852-94D9124B-E14E-4AC5-A848-45E24D54E910Q34627039-A78A9615-5500-4576-8410-BFEB74FEDBDBQ34672401-D363BA90-92F7-4E62-86F3-6664920FA65AQ35083012-CAD9D86B-D928-43F6-BDF6-C2CDFBAEF59BQ35130598-6B2C5409-1F92-4D71-A84C-2548297E7BEBQ35147247-6BC80CCB-ED7E-4CDC-9738-300C50552C1DQ35626866-3660AF4E-D858-4C11-9B51-1BBD1D0F914DQ35653704-55604064-E07B-4E63-B8CF-F128A32F7356Q35766843-65B20C9F-7DBC-4E2D-9204-1FAA108F432EQ35788740-775F0B75-E6A7-4165-AA29-FF2A4FDB64E2Q36239388-E4C5259E-FCA4-4ED1-A1B0-1FB883E017BEQ36241571-36B54FDB-6FE5-4770-A250-DB6115AA40FFQ36282175-9AB82DB3-94B9-40DE-A51F-26C71F5AECD3Q36579400-63CC0D7C-DD00-45FE-9829-71B566DC5183Q36733079-44F5E375-2A95-48A1-93BB-104845697D6EQ36870059-C10987EB-CE18-4C10-9B0D-AB1E18E7DCD4Q37150901-070E4805-11EC-4A4E-A0DB-BB89AF9DC6BEQ37155167-F973ED3E-E5A2-4FFC-9434-FB838899B04BQ37177646-E5858C53-A36A-430F-995B-E8F28088FF02Q37211041-D8F20C05-EE4E-401C-A671-94194B28572AQ37231353-8EF3E54B-0CCF-48BF-8E53-684AD8C58ED9Q37404672-0C10EAB2-6BFE-427B-AE84-4234CA2D5F03Q37405580-0CF4D46A-0093-4025-B61A-43022AB6C18AQ37418337-7BA09029-EB05-4C8B-ADE9-BB0D8EFC896DQ37602482-E09ADE55-D3D1-4DD2-A8E3-98BCAF66C6CCQ37612221-BBE1B73D-AB9F-4475-8D81-6827B6AADB00Q37621962-D2E7016D-E139-4CD4-8113-0FFC8CDB577CQ37686313-02E69B9A-9CD7-4C49-B818-7E9C28CE636EQ37754970-85506E8A-8A16-455D-B503-09E28C977EE9Q37766243-4BC32DFD-CA8A-494B-81B9-3831DBD2101EQ37908105-2D3F76FA-540A-4E35-BCCD-3A09488849D8Q38314276-AC16B44F-06DF-404A-B31D-951698B56902
P2860
Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Uncontrolled asthma: a review ...... den and options for treatment.
@ast
Uncontrolled asthma: a review ...... den and options for treatment.
@en
type
label
Uncontrolled asthma: a review ...... den and options for treatment.
@ast
Uncontrolled asthma: a review ...... den and options for treatment.
@en
prefLabel
Uncontrolled asthma: a review ...... den and options for treatment.
@ast
Uncontrolled asthma: a review ...... den and options for treatment.
@en
P2093
P1433
P1476
Uncontrolled asthma: a review ...... den and options for treatment.
@en
P2093
Colin Reisner
Gary Ferguson
Stephen P Peters
Yamo Deniz
P304
P356
10.1016/J.RMED.2006.03.031
P577
2006-05-18T00:00:00Z